ANALOGUES OF VDAC1-DERlVED PEPTIDES
AssigneesB. G. Negev Technologies and Applications Ltd., At Ben-Gurion Unlversity, The National Institute for Biotechnology In the Negev Ltd.
InventorVarda SHOSHAN-BARMATZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto
Claims16
A method of treating and/or preventing non-alcoholic fatty liver disease (NAFLD) and/or a symptom associated with NAFLD, the method comprises administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one synthetic peptide, the synthetic peptide comprising an analogue of VDAC1-derived peptide, the VDAC1-derived peptide is capable of inducing apoptosis in cancerous cells and consists of 5-26 contiguous amino acids, wherein the analogue is retro modified and partially or completely inverso modified with respect to the VDAC1-derived peptide, thereby treating and/or preventing the non-alcoholic fatty liver disease (NAFLD) and/or the symptom associated thereto.
Dependencies are inferred from the claim text.